{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:38:34Z","timestamp":1784039914891,"version":"3.55.0"},"reference-count":81,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Bone and joint infections (BJI) require prolonged antimicrobial treatment, leading to lengthy hospitalizations, high costs, the risk of nosocomial infections, and the development of antimicrobial resistance. Dalbavancin is a novel semisynthetic lipoglycopeptide approved for the treatment of adults and children with acute bacterial skin and skin structure infections. This narrative review aims to summarize the characteristics of dalbavancin and the current scientific evidence regarding its clinical efficacy and safety in the treatment of BJI. A literature search until June 2023 was performed to identify all published research about the role of dalbavancin in the management of BJI. Due to its unique pharmacokinetics characterized by prolonged half-life, high bactericidal activity against most Gram-positive bacteria, a good safety profile, and high tissue penetration, dalbavancin can be a valuable alternative to the treatment of BJI. Clinical studies have shown its non-inferiority compared to conventional therapies in BJI, offering potent activity against key pathogens and an extended dosing interval that may shorten hospitalization. In conclusion, dalbavancin represents a promising treatment option for BJI with a favorable safety profile, but further research in both adults and particularly children, who are ideal candidates for long-acting antibiotics, is necessary to evaluate the role of dalbavancin in BJI.<\/jats:p>","DOI":"10.3390\/antibiotics12101492","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T02:47:30Z","timestamp":1695955650000},"page":"1492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections"],"prefix":"10.3390","volume":"12","author":[{"given":"Dimitra","family":"Dimopoulou","sequence":"first","affiliation":[{"name":"Second Department of Pediatrics, \u201cAghia Sophia\u201d Children\u2019s Hospital, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7837-9733","authenticated-orcid":false,"given":"Elpis","family":"Mantadakis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University General Hospital of Alexandroupolis, 681 00 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Koutserimpas","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics and Traumatology, \u201c251\u201d Hellenic Air Force General Hospital of Athens, 115 25 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Samonis","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Crete, 715 00 Heraklion, Greece"},{"name":"First Department of Medical Oncology, \u201cMetropolitan\u201d Hospital, 185 47 Attica, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7861\/clinmedicine.18-2-150","article-title":"Bone and Joint Infection","volume":"18","author":"Colston","year":"2018","journal-title":"Clin. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.mpmed.2021.12.008","article-title":"Bone and Joint Infections","volume":"50","author":"Mathews","year":"2022","journal-title":"Medicine"},{"key":"ref_4","first-page":"95","article-title":"Bone and Joint Infections","volume":"28","author":"Darton","year":"2010","journal-title":"Surgery"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jac\/dkh191","article-title":"Antibiotic Treatment of Gram-Positive Bone and Joint Infections","volume":"53","author":"Darley","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jpids\/piab027","article-title":"Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics","volume":"10","author":"Woods","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa2020198","article-title":"Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection","volume":"384","author":"Bernard","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1592\/phco.27.7.1001","article-title":"Burden of Methicillin-Resistant Staphylococcus Aureus: Focus on Clinical and Economic Outcomes","volume":"27","author":"Lodise","year":"2007","journal-title":"Pharmacotherapy"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Styers, D., Sheehan, D.J., Hogan, P., and Sahm, D.F. (2006). Laboratory-Based Surveillance of Current Antimicrobial Resistance Patterns and Trends among Staphylococcus Aureus: 2005 Status in the United States. Ann. Clin. Microbiol. Antimicrob., 5.","DOI":"10.1186\/1476-0711-5-2"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1590\/S0074-02762011000100008","article-title":"High Vancomycin Resistance among Biofilms Produced by Staphylococcus Species Isolated from Central Venous Catheters","volume":"106","author":"Antunes","year":"2011","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/JCM.02187-13","article-title":"Report of the 13th Vancomycin-Resistant Staphylococcus Aureus Isolate from the United States","volume":"52","author":"Limbago","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","article-title":"Daptomycin: A Lipopeptide Antibiotic for the Treatment of Serious Gram-Positive Infections","volume":"55","author":"Steenbergen","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/B978-0-12-820472-6.00138-9","article-title":"Daptomycin","volume":"7","author":"Cave","year":"2022","journal-title":"Compr. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","article-title":"Oxazolidinone Antibiotics","volume":"358","author":"Diekema","year":"2001","journal-title":"Lancet"},{"key":"ref_17","unstructured":"Azzouz, A., and Preuss, C.V. (2023). Linezolid, StatPearls."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.clinthera.2015.11.007","article-title":"Beyond Vancomycin: The Tail of the Lipoglycopeptides","volume":"37","author":"Klinker","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1089\/sur.2020.413","article-title":"Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections","volume":"22","author":"Cooper","year":"2021","journal-title":"Surg. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/INF.0000000000001538","article-title":"Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age","volume":"36","author":"Gonzalez","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgar.2020.11.018","article-title":"Efficacy and Safety of Dalbavancin in the Treatment of Gram-Positive Bacterial Infections","volume":"24","author":"Wang","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2146\/ajhp070255","article-title":"Dalbavancin: A New Lipoglycopeptide Antibiotic","volume":"65","author":"Bailey","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/23744235.2017.1296968","article-title":"Review of the Pharmacokinetics of Dalbavancin, a Recently Approved Lipoglycopeptide Antibiotic","volume":"49","author":"Dash","year":"2017","journal-title":"Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0091270008330162","article-title":"Pharmacokinetics of Dalbavancin in Patients with Renal or Hepatic Impairment","volume":"49","author":"Marbury","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.01264-06","article-title":"In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin","volume":"51","author":"Andes","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter Clinical Experience of Real Life Dalbavancin Use in Gram-Positive Infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/INF.0000000000000646","article-title":"Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12\u201317 Years of Age","volume":"34","author":"Bradley","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ijantimicag.2017.12.011","article-title":"Dalbavancin In-Vitro Activity Obtained against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in US and European Hospitals (2011\u20132016)","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of Dalbavancin and Comparator Agents against Gram-Positive Cocci from Clinical Infections in the USA and Europe 2015\u20132016","volume":"73","author":"Pfaller","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1093\/jac\/dkaa163","article-title":"Efficacy of Dalbavancin against MRSA Biofilms in a Rat Model of Orthopaedic Implant-Associated Infection","volume":"75","author":"Silva","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/1120009X.2021.1911518","article-title":"Anti-Biofilm Activity of Dalbavancin against Methicillin-Resistant Staphylococcus Aureus (MRSA) Isolated from Human Bone Infection","volume":"33","author":"Silva","year":"2021","journal-title":"J. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/AAC.00274-15","article-title":"In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus Aureus Isolates from a Global Surveillance Program","volume":"59","author":"McCurdy","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","article-title":"Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies","volume":"39","author":"Dunne","year":"2016","journal-title":"Drug Saf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40261-021-01028-3","article-title":"Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections","volume":"41","author":"Poliseno","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Antosz, K., Al-Hasan, M.N., Lu, Z.K., Tabor, B., Justo, J.A., Milgrom, A., Kohn, J., and Bookstaver, P.B. (2021). Clinical Utility and Cost Effectiveness of Long-Acting Lipoglycopeptides Used in Deep-Seated Infections among Patients with Social and Economic Barriers to Care. Pharmacy, 10.","DOI":"10.3390\/pharmacy10010001"},{"key":"ref_41","first-page":"Doc03","article-title":"Potential Savings through Single-Dose Intravenous Dalbavancin in Long-Term MRSA Infection Treatment\u2014A Health Economic Analysis Using German DRG Data","volume":"7","author":"Wilke","year":"2019","journal-title":"GMS Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-World Experience with Dalbavancin Therapy in Gram-Positive Skin and Soft Tissue Infection, Bone and Joint Infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Brescini, L., Della Martera, F., Morroni, G., Mazzanti, S., Di Pietrantonio, M., Mantini, P., Candelaresi, B., Pallotta, F., Olivieri, S., and Iencinella, V. (2021). Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091129"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsps.2020.02.007","article-title":"Dalbavancin versus Standard of Care for the Treatment of Osteomyelitis in Adults: A Retrospective Matched Cohort Study","volume":"28","author":"Almangour","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","article-title":"Efficacy and Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) and Other Infections in a Real-Life Setting: Data from an Italian Observational Multicentric Study (DALBITA Study)","volume":"18","author":"Bai","year":"2020","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/idr14020032","article-title":"Evaluating the Use of Dalbavancin for Off-Label Indications","volume":"14","author":"Taylor","year":"2022","journal-title":"Infect. Dis. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the Treatment of Different Gram-Positive Infections: A Real-Life Experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"ofab589","DOI":"10.1093\/ofid\/ofab589","article-title":"Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-World Analysis","volume":"9","author":"Cain","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the Management of Gram-Positive Osteomyelitis: Effectiveness and Potential Utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- And off-Label Utilization of Dalbavancin and Oritavancin for Gram-Positive Infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"ofaa293","DOI":"10.1093\/ofid\/ofaa293","article-title":"Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy","volume":"7","author":"Shihadeh","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ejhpharm-2018-001711","article-title":"Dalbavancin Is a Novel Antimicrobial against Gram-Positive Pathogens: Clinical Experience beyond Labelled Indications","volume":"27","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","article-title":"French National Cohort of First Use of Dalbavancin: A High Proportion of off-Label Use","volume":"54","author":"Dinh","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jgar.2019.03.015","article-title":"Clinical Experience with Dalbavancin for the Treatment of Deep Sternal Wound Infection","volume":"18","author":"Bartoletti","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"ofz028","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as Secondary Therapy for Serious Staphylococcus Aureus Infections in a Vulnerable Patient Population","volume":"6","author":"Beieler","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Jame, W., Basgut, B., and Abdi, A. (2021). Efficacy and Safety of Novel Glycopeptides versus Vancomycin for the Treatment of Gram-Positive Bacterial Infections Including Methicillin Resistant Staphylococcus Aureus: A Systematic Review and Meta-Analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260539"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/INF.0000000000003798","article-title":"The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections","volume":"42","author":"Giorgobiani","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Castellazzi, L., Mantero, M., and Esposito, S. (2016). Update on the Management of Pediatric Acute Osteomyelitis and Septic Arthritis. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060855"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Lovatti, S., Tiecco, G., Mul\u00e9, A., Rossi, L., Sforza, A., Salvi, M., Signorini, L., Castelli, F., and Quiros-Roldan, E. (2023). Dalbavancin in Bone and Joint Infections: A Systematic Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16071005"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"ofab486","DOI":"10.1093\/ofid\/ofab486","article-title":"Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review","volume":"8","author":"Cooper","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14787210.2021.1894130","article-title":"The Role of Dalbavancin for Gram Positive Infections in the COVID-19 Era: State of the Art and Future Perspectives","volume":"19","author":"Andreoni","year":"2021","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/1120009X.2021.2015649","article-title":"Dalbavancin Treatment for Spondylodiscitis: Multi-Center Clinical Experience and Literature Review","volume":"34","author":"Ramadan","year":"2022","journal-title":"J. Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.ijantimicag.2020.106210","article-title":"Comparison of Dalbavancin to Standard-of-Care for Outpatient Treatment of Invasive Gram-Positive Infections","volume":"56","author":"Veve","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am. J. Case Rep."},{"key":"ref_66","first-page":"26","article-title":"Diabetic Foot Infections: A Comprehensive Overview","volume":"23","author":"Pitocco","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/jac\/dkab117","article-title":"In Vitro Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Diabetic Foot Osteomyelitis","volume":"76","author":"Pantel","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_68","first-page":"296","article-title":"Experience in the Use of Dalbavancin in Diabetic Foot Infection","volume":"40","year":"2022","journal-title":"Enfermedades Infecc. Microbiol. Clin."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5455\/medarh.2020.74.243-245","article-title":"Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin","volume":"74","author":"Loupa","year":"2020","journal-title":"Med. Arch."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.arth.2018.02.078","article-title":"The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria","volume":"33","author":"Parvizi","year":"2018","journal-title":"J Arthroplast."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1093\/jac\/dkac178","article-title":"Dalbavancin in Gram-Positive Periprosthetic Joint Infections","volume":"77","author":"Simon","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_72","first-page":"532","article-title":"Dalbavancin for Treating Prosthetic Joint Infections Caused by Gram-Positive Bacteria: A Proposal for a Low Dose Strategy. A Retrospective Cohort Study","volume":"32","year":"2019","journal-title":"Rev. Esp. Quim."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jgar.2021.03.026","article-title":"Dalbavancin Treatment for Prosthetic Joint Infections in Real-Life: A National Cohort Study and Literature Review","volume":"25","author":"Matt","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1185602","DOI":"10.3389\/fphar.2023.1185602","article-title":"Dalbavancin as Suppressive Antibiotic Therapy in Patients with Prosthetic Infections: Efficacy and Safety","volume":"14","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijantimicag.2013.05.019","article-title":"Activity of Dalbavancin, Alone and in Combination with Rifampicin, against Meticillin-Resistant Staphylococcus Aureus in a Foreign-Body Infection Model","volume":"42","author":"Baldoni","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10096-016-2845-z","article-title":"Dalbavancin Reduces Biofilms of Methicillin-Resistant Staphylococcus Aureus (MRSA) and Methicillin-Resistant Staphylococcus Epidermidis (MRSE)","volume":"36","author":"Knafl","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"\u017diemyt\u0117, M., Rodr\u00edguez-D\u00edaz, J.C., Ventero, M.P., Mira, A., and Ferrer, M.D. (2020). Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00553"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkv357","article-title":"Efficacy of Dalbavancin in the Treatment of MRSA Rat Sternal Osteomyelitis with Mediastinitis","volume":"71","author":"Barnea","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Di Pilato, V., Ceccherini, F., Sennati, S., D\u2019Agostino, F., Arena, F., D\u2019Atanasio, N., Di Giorgio, F.P., Tongiani, S., Pallecchi, L., and Rossolini, G.M. (2020). In Vitro Time-Kill Kinetics of Dalbavancin against Staphylococcus Spp. Biofilms over Prolonged Exposure Times. Diagn. Microbiol. Infect. Dis., 96.","DOI":"10.1016\/j.diagmicrobio.2019.114901"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jinf.2004.05.006","article-title":"Dalbavancin Compared with Vancomycin for Prevention of Staphylococcus Aureus Colonization of Devices in Vivo","volume":"50","author":"Darouiche","year":"2005","journal-title":"J. Infect."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Somolinos, M., D\u00edaz-Navarro, M., Benjumea, A., Tormo, M., Matas, J., Vaquero, J., Mu\u00f1oz, P., Sanz-Ru\u00edz, P., and Guembe, M. (2022). Determination of the Elution Capacity of Dalbavancin in Bone Cements: New Alternative for the Treatment of Biofilm-Related Peri-Prosthetic Joint Infections Based on an In Vitro Study. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101300"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/10\/1492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:01:26Z","timestamp":1760130086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/10\/1492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":81,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["antibiotics12101492"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12101492","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}